Novartis Committed to Sandoz generic business: CEO Vas Narasimhan
Zurich: Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pandemic."We remain committed to the Sandoz business," Narasimhan said during the company's annual results news conference, when asked about the Swiss company's plans for the generics unit that over...
Zurich: Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pandemic.
"We remain committed to the Sandoz business," Narasimhan said during the company's annual results news conference, when asked about the Swiss company's plans for the generics unit that over the years has been subject of disposal or spin-off speculation.
Novartis's fourth-quarter results on Tuesday missed analyst forecasts. Narasimhan also announced a revamp of his digital operations, including the exit of Chief Digital Officer Bertrand Bodson.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd